Recursion Enters Into Agreements To Acquire Cyclica And Valence To Bolster Chemistry And Generative Ai Capabilities

Recursion, a leading clinical stage TechBio company, has announced the acquisition of two companies in the AI-enabled drug discovery space: Cyclica and Valence. The acquisitions will enable Recursion to deploy the most complete, technology-enabled drug discovery solution in the biopharma industry, combining large-scale automated wet-laboratories and supercomputing capabilities with Cyclica’s industry-leading capabilities in digital chemistry and machine-learning and artificial intelligence. Cyclica’s MatchMaker product, an AI-enabled deep learning engine, will be integrated into the RecursionOS and will be used to predict the polypharmacology of small molecules as the foundation for small molecule drug discovery.